• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

同时定量检测血液流变学和氧饱和度,以评估镰状细胞病的亲和修饰治疗。

Simultaneous quantification of blood rheology and oxygen saturation to evaluate affinity-modifying therapies in sickle cell disease.

机构信息

Department of Biomedical Engineering, University of Minnesota, Minneapolis 55409, USA.

出版信息

Lab Chip. 2022 Oct 25;22(21):4141-4150. doi: 10.1039/d2lc00623e.

DOI:10.1039/d2lc00623e
PMID:36134535
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10165883/
Abstract

Sickle cell blood demonstrates oxygen-dependent flow behavior as a result of HbS polymerization during hypoxia, and these rheological changes provide a biophysical metric that can be used to quantify the pathological behavior of the blood. Relating these rheological changes directly to hemoglobin oxygen saturation would improve our understanding of SCD pathogenesis and the potential effects of therapeutic drugs. Towards this end, we have developed a microfluidic platform capable of spectrophotometric quantification of Hb-O saturation and simultaneous evaluation of the accompanying rheological changes in SCD blood flow. We demonstrated the ability to measure changes in Hb-O affinity and a restoration of oxygen-independent blood flow behavior after incubation with voxelotor, an oxygen affinity modifying drug approved for use in SCD. We also identified regimes in Hb-O saturation where the effects of HbS polymerization begin to take effect in contributing to pathological flow behavior, independent of voxelotor treatment. In contrast, incubation with voxelotor recovered oxygen-dependent blood flow over a range of , providing a framework for understanding voxelotor's therapeutic effect in lowering the at which the requisite Hb-O saturation is reached to observe pathological blood flow. These results help explain the mechanistic effects of voxelotor and show the potential of this platform to identify affinity-modifying compounds and evaluate their therapeutic effect on blood flow.

摘要

镰状细胞血液在缺氧时由于 HbS 聚合而表现出氧依赖性流动行为,这些流变学变化提供了一种可以用来量化血液病理行为的生物物理指标。将这些流变学变化直接与血红蛋白氧饱和度相关联,可以提高我们对 SCD 发病机制和治疗药物潜在影响的理解。为此,我们开发了一种微流控平台,能够对 Hb-O 饱和度进行分光光度定量,并同时评估 SCD 血流中伴随的流变学变化。我们证明了在与 voxelotor(一种用于 SCD 的氧亲和力修饰药物)孵育后,能够测量 Hb-O 亲和力的变化,并恢复氧非依赖性血流行为。我们还确定了 Hb-O 饱和度的范围,其中 HbS 聚合的影响开始对病理流动行为产生影响,而与 voxelotor 治疗无关。相比之下,voxelotor 的孵育在一定的范围内恢复了氧依赖性血流,为理解 voxelotor 通过降低达到观察病理血流所需的 Hb-O 饱和度来降低疾病严重程度的治疗效果提供了框架。这些结果有助于解释 voxelotor 的机制作用,并展示了该平台识别亲和力修饰化合物并评估其对血流治疗效果的潜力。

相似文献

1
Simultaneous quantification of blood rheology and oxygen saturation to evaluate affinity-modifying therapies in sickle cell disease.同时定量检测血液流变学和氧饱和度,以评估镰状细胞病的亲和修饰治疗。
Lab Chip. 2022 Oct 25;22(21):4141-4150. doi: 10.1039/d2lc00623e.
2
Model-informed drug development of voxelotor in sickle cell disease: Exposure-response analysis to support dosing and confirm mechanism of action.基于模型的罗沙司他治疗镰状细胞病的药物研发:暴露-反应分析以支持剂量选择并确认作用机制。
CPT Pharmacometrics Syst Pharmacol. 2022 Jun;11(6):698-710. doi: 10.1002/psp4.12780. Epub 2022 Apr 21.
3
Design, Synthesis, and Evaluation of Allosteric Effectors for Hemoglobin.血红蛋白别构效应剂的设计、合成与评价。
Acc Chem Res. 2023 Jun 6;56(11):1279-1286. doi: 10.1021/acs.accounts.2c00590. Epub 2023 Mar 22.
4
Increased hemoglobin affinity for oxygen with GBT1118 improves hypoxia tolerance in sickle cell mice.GBT1118 增加血红蛋白对氧气的亲和力可提高镰状细胞小鼠的缺氧耐受力。
Am J Physiol Heart Circ Physiol. 2021 Aug 1;321(2):H400-H411. doi: 10.1152/ajpheart.00048.2021. Epub 2021 Jul 2.
5
Voxelotor for the treatment of sickle cell disease in pediatric patients.用于治疗儿科患者镰状细胞病的武利尤单抗。
Expert Rev Hematol. 2022 Jun;15(6):485-492. doi: 10.1080/17474086.2022.2082408. Epub 2022 Jun 7.
6
An expert review of voxelotor for the treatment of hemolytic anemia in patients with sickle cell disease: 'bridging the gap between laboratory data and patient related outcomes'.关于伏索利托治疗镰状细胞病患者溶血性贫血的专家综述:“弥合实验室数据与患者相关结局之间的差距”
Expert Rev Hematol. 2023 Jul-Dec;16(8):585-591. doi: 10.1080/17474086.2023.2226858. Epub 2023 Jun 22.
7
Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.系统性评价罗特西普:首个镰状血红蛋白聚合抑制剂类药物用于镰状细胞病的治疗。
Pharmacotherapy. 2020 Jun;40(6):525-534. doi: 10.1002/phar.2405. Epub 2020 May 19.
8
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.一项针对镰状细胞病患者的 voxotor 的 3 期随机试验。
N Engl J Med. 2019 Aug 8;381(6):509-519. doi: 10.1056/NEJMoa1903212. Epub 2019 Jun 14.
9
Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease.依他沃吡,一种红细胞丙酮酸激酶激活剂,用于治疗镰状细胞病。
J Pharmacol Exp Ther. 2022 Mar;380(3):210-219. doi: 10.1124/jpet.121.000743. Epub 2022 Jan 14.
10
MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease.甲硫氨酸氨肽酶2(MetAP2)抑制作用可改变血红蛋白S,延缓其聚合,并改善镰状细胞病的血流。
Blood Adv. 2021 Mar 9;5(5):1388-1402. doi: 10.1182/bloodadvances.2020003670.

引用本文的文献

1
Oxygen-tunable endothelialized microvascular chip to assess hypoxia-reperfusion in sickle cell disease.用于评估镰状细胞病中缺氧再灌注的氧可调内皮化微血管芯片
Lab Chip. 2025 Aug 20. doi: 10.1039/d5lc00211g.

本文引用的文献

1
Feature tracking microfluidic analysis reveals differential roles of viscosity and friction in sickle cell blood.特征跟踪微流控分析揭示了粘度和摩擦力在镰状细胞血液中的不同作用。
Lab Chip. 2022 Apr 12;22(8):1565-1575. doi: 10.1039/d1lc01133b.
2
Effects of Genotypes and Treatment on Oxygenscan Parameters in Sickle Cell Disease.基因型和治疗对镰状细胞病血氧扫描参数的影响。
Cells. 2021 Apr 5;10(4):811. doi: 10.3390/cells10040811.
3
VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions.
VZHE-039,一种新型抗镰变剂,可预防缺氧和缺氧条件下的红细胞镰变。
Sci Rep. 2020 Nov 20;10(1):20277. doi: 10.1038/s41598-020-77171-2.
4
5-(Hydroxymethyl)furfural restores low-oxygen rheology of sickle trait blood in vitro.5-(羟甲基)糠醛可恢复体外镰状细胞特征血液的低氧流变性。
Br J Haematol. 2020 Mar;188(6):985-993. doi: 10.1111/bjh.16251. Epub 2019 Dec 30.
5
A microfluidic platform for simultaneous quantification of oxygen-dependent viscosity and shear thinning in sickle cell blood.一种用于同时定量镰状细胞血液中氧依赖性粘度和剪切变稀的微流控平台。
APL Bioeng. 2019 Nov 15;3(4):046102. doi: 10.1063/1.5118212. eCollection 2019 Dec.
6
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.一项针对镰状细胞病患者的 voxotor 的 3 期随机试验。
N Engl J Med. 2019 Aug 8;381(6):509-519. doi: 10.1056/NEJMoa1903212. Epub 2019 Jun 14.
7
Partial pressure of oxygen in the human body: a general review.人体中的氧分压:综述
Am J Blood Res. 2019 Feb 15;9(1):1-14. eCollection 2019.
8
Red blood cell storage lesion: causes and potential clinical consequences.红细胞储存损伤:原因及潜在临床后果。
Blood Transfus. 2019 Jan;17(1):27-52. doi: 10.2450/2019.0217-18.
9
GBT440 reverses sickling of sickled red blood cells under hypoxic conditions .GBT440可在缺氧条件下逆转镰状红细胞的镰变。
Hematol Rep. 2018 May 14;10(2):7419. doi: 10.4081/hr.2018.7419.
10
GBT440 improves red blood cell deformability and reduces viscosity of sickle cell blood under deoxygenated conditions.GBT440在脱氧条件下可改善镰状细胞血液的红细胞变形能力并降低其粘度。
Clin Hemorheol Microcirc. 2018;70(1):95-105. doi: 10.3233/CH-170340.